As of November 6, 2026, 10 holders' latest Schedule 13D or 13G filings report owning 5% or more of iBio, Inc. The largest reported stake is Affinity Asset Advisors, LLC's, at 9.99%. 30 filings are on record since July 30, 2025 (Schedule 13G/A, August 13, 2026).
Sell to companies like iBio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Coastlands Capital LP · Sole voting: 0 · Shared voting: 6,247,738 · Sole dispositive: 0 · Shared dispositive: 6,247,738 · SCHEDULE 13G, 2026-10-14
- · Reporting person: Cormorant Asset Management, LP · Sole voting: 0 · Shared voting: 5,117,481 · Sole dispositive: 0 · Shared dispositive: 5,117,481 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Vestal Point Capital, LP · Sole voting: 0 · Shared voting: 4,025,000 · Sole dispositive: 0 · Shared dispositive: 4,025,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Lynx1 Capital Management LP · Sole voting: 0 · Shared voting: 2,807,016 · Sole dispositive: 0 · Shared dispositive: 2,807,016 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Affinity Asset Advisors, LLC · Sole voting: 5,068,882 · Shared voting: 0 · Sole dispositive: 5,068,882 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
iBio, Inc. has 30 Schedule 13D or 13G filings on record since 2025-07-30. 10 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 9.99% | 5,068,882 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Adage Capital Management, L.P. | 9.99% | 2,181,422 | SCHEDULE 13G, 2025-11-13 | 2025-09-30 |
| SilverArc Capital Management, LLC | 9.99% | 2,181,422 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| Cormorant Asset Management, LP | 9.99% | 5,117,481 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Sirenia Capital Management LP | 9.9% | 11,586,340 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Coastlands Capital LP | 9.72% | 6,247,738 | SCHEDULE 13G, 2026-10-14 | 2026-10-07 |
| Vestal Point Capital, LP | 7.9% | 4,025,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Frazier Life Sciences Public Fund, L.P. | 5.7% | 1,953,467 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 |
| Lynx1 Capital Management LP | 5.4% | 2,807,016 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Integrated Core Strategies (US) LLC | 5.2% | 1,234,295 | SCHEDULE 13G, 2026-01-22 | 2026-01-15 |
| Ikarian Capital, LLC | 4.99% | 1,151,051 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| EcoR1 Capital, LLC | 4.6% | 1,583,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| ADAR1 Capital Management, LLC | 4.4% | 1,351,671 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| 3.1% | 847,044 | SCHEDULE 13G/A, 2025-07-30 | 2025-06-30 | |
| Point72 Asset Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Logos Global Management LP | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind iBio, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on iBio, Inc. and the records around it.
iBio, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Company profile and every filing Jan 2026
- Form D filing Jan 2026
- Form D filing May 2025
- Who owns it
Companies that share a holder
- Patrick J. Crutcher also filed stake reports on 1 other company: Avalo Therapeutics, Inc. (Aug 2025)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026)
Watch iBio, Inc.
Get an email when iBio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on iBio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on iBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on iBio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
35 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 5,068,882 | 0 | 5,068,882 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Michael Cho | 5,068,882 | 0 | 5,068,882 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Cormorant Asset Management, LP | 0 | 5,117,481 | 0 | 5,117,481 | SCHEDULE 13G/A, 2026-08-14 |
| Bihua Chen | 0 | 5,117,481 | 0 | 5,117,481 | SCHEDULE 13G/A, 2026-08-14 |
| Coastlands Capital LP | 0 | 6,247,738 | 0 | 6,247,738 | SCHEDULE 13G, 2026-10-14 |
| Coastlands Capital Partners LP | 0 | 6,247,738 | 0 | 6,247,738 | SCHEDULE 13G, 2026-10-14 |
| Coastlands Capital GP LLC | 0 | 6,247,738 | 0 | 6,247,738 | SCHEDULE 13G, 2026-10-14 |
| Coastlands Capital LLC | 0 | 6,247,738 | 0 | 6,247,738 | SCHEDULE 13G, 2026-10-14 |
| Matthew D. Perry | 0 | 6,247,738 | 0 | 6,247,738 | SCHEDULE 13G, 2026-10-14 |
| Vestal Point Capital, LP | 0 | 4,025,000 | 0 | 4,025,000 | SCHEDULE 13G/A, 2026-08-14 |
| Ryan Wilder | 0 | 4,025,000 | 0 | 4,025,000 | SCHEDULE 13G/A, 2026-08-14 |
| Lynx1 Capital Management LP | 0 | 2,807,016 | 0 | 2,807,016 | SCHEDULE 13G, 2026-08-14 |
| Weston Nichols | 0 | 2,807,016 | 0 | 2,807,016 | SCHEDULE 13G, 2026-08-14 |
The latest filing identifies iBio, Inc. by CUSIP 451033708 and gives its principal executive office as 11750 Sorrento Valley Road, Suite 200, San Diego, CA 92121 (SCHEDULE 13G, 2026-10-14).
What the percentages are based on
As of June 30, 2026, the Reporting Persons beneficially own approximately 9.99% of the Common Stock outstanding.Affinity Asset Advisors, LLC, SCHEDULE 13G/A, 2026-08-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-30 | Patrick J. Crutcher | 3.1% | SCHEDULE 13G/A |
| 2025-08-14 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2025-08-25 | Point72 Asset Management, L.P. | 9.9% | SCHEDULE 13G |
| 2025-08-26 | Affinity Healthcare Fund, LP | 9.99% | SCHEDULE 13G |
| 2025-11-13 | Adage Capital Management, L.P. | 9.99% | SCHEDULE 13G |
| 2025-11-14 | Vestal Point Capital, LP | 9.9% | SCHEDULE 13G |
| 2025-11-14 | SilverArc Capital Management, LLC | 9.99% | SCHEDULE 13G |
| 2025-11-14 | Cormorant Asset Management, LP | 9.99% | SCHEDULE 13G |
| 2025-11-14 | Ikarian Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2025-12-03 | Affinity Asset Advisors, LLC | 9.99% | SCHEDULE 13G/A |
| 2025-12-16 | Frazier Life Sciences Public Fund, L.P. | 8.7% | SCHEDULE 13G |
| 2025-12-17 | EcoR1 Capital, LLC | 9.9% | SCHEDULE 13G |
| 2025-12-19 | Logos Global Management LP | 8.9% | SCHEDULE 13G |
| 2026-01-22 | Integrated Core Strategies (US) LLC | 5.2% | SCHEDULE 13G |
| 2026-01-29 | Affinity Asset Advisors, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | Lynx1 Capital Management LP | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Logos Global Management LP | 4.6% | SCHEDULE 13G/A |
| 2026-02-17 | ADAR1 Capital Management, LLC | 4.4% | SCHEDULE 13G/A |
| 2026-05-12 | Frazier Life Sciences Public Fund, L.P. | 5.7% | SCHEDULE 13G/A |
| 2026-05-14 | Affinity Asset Advisors, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-05-15 | Sirenia Capital Management LP | 9.9% | SCHEDULE 13G |
| 2026-05-15 | Point72 Asset Management, L.P. | 0% | SCHEDULE 13G/A |
| 2026-05-15 | EcoR1 Capital, LLC | 4.6% | SCHEDULE 13G/A |
| 2026-05-15 | Logos Global Management LP | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Cormorant Asset Management, LP | 9.99% | SCHEDULE 13G/A |
| 2026-08-13 | Affinity Asset Advisors, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | Vestal Point Capital, LP | 7.9% | SCHEDULE 13G/A |
| 2026-08-14 | Lynx1 Capital Management LP | 5.4% | SCHEDULE 13G |
| 2026-08-14 | Cormorant Asset Management, LP | 9.99% | SCHEDULE 13G/A |
| 2026-10-14 | Coastlands Capital LP | 9.72% | SCHEDULE 13G |
Questions about who owns iBio, Inc.
Who owns iBio, Inc.?
On this page, 10 holders' latest ownership filings report 5% or more of iBio, Inc.: Affinity Asset Advisors, LLC (9.99%, Schedule 13G/A, filed 2026-08-13), Adage Capital Management, L.P. (9.99%, Schedule 13G, filed 2025-11-13), SilverArc Capital Management, LLC (9.99%, Schedule 13G, filed 2025-11-14), Cormorant Asset Management, LP (9.99%, Schedule 13G/A, filed 2026-08-14) and Sirenia Capital Management LP (9.9%, Schedule 13G, filed 2026-05-15); 5 more are listed above.
Who are the largest shareholders of iBio, Inc.?
By the share each holder's latest filing reports, the largest holders of iBio, Inc. on this page are Affinity Asset Advisors, LLC (9.99%), Adage Capital Management, L.P. (9.99%) and SilverArc Capital Management, LLC (9.99%).
When did Affinity Asset Advisors, LLC buy into iBio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Affinity Asset Advisors, LLC on this page is the Schedule 13G/A, filed 2025-12-03, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-13, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 30 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for iBio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 4, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 8, 2026 | Leadership change: Elizabeth Stoner appointed, Director, and 1 more | — | Leadership changes | Source |
| January 22, 2026 | Form D, private offering | $25.99M sold | Form D page | Source |
| May 7, 2025 | Form D, private offering | $11.08M sold | Form D page | Source |
| October 24, 2014 | Court case: Andavarapu v. iBio Inc., District Court, D. Delaware | — | Court records | Source |
iBio, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for iBio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.